This is a news story, published by Yahoo, that relates primarily to Zepbound news.
For more Zepbound news, you can click here:
more Zepbound newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Sleep apnea patients. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest diabetes drug news, obstructive sleep apnea news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
sleep apneaReuters
•Health
Health
77% Informative
U.S. Food and Drug Administration approves Eli Lilly's weight-loss treatment, Zepbound , for obstructive sleep apnea.
It is the first drug greenlighted to directly treat patients with the common sleeping disorder.
Sleep apnea patients stop breathing briefly while sleeping, disturbing the sleep cycle and causing long-term complications.
VR Score
85
Informative language
91
Neutral language
50
Article tone
formal
Language
English
Language complexity
58
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links
